Savara(US:SVRA) Globenewswire·2025-10-08 15:28Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Savara securities lawsuit is from March 7, 2024, to May 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the court by November 7, 2025, to serve as lead plaintiff [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Savara made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital [4] - The lawsuit asserts that the public statements made by Savara were materially false and misleading, leading to investor damages when the truth was revealed [4]